Recessive mutations in MSTO1 cause mitochondrial dynamics impairment, leading to myopathy and ataxia by Nasca, A et al.
Received: 16November 2016 Revised: 10May 2017 Accepted: 12May 2017
DOI: 10.1002/humu.23262
B R I E F R E PORT
Recessivemutations inMSTO1 causemitochondrial dynamics
impairment, leading tomyopathy and ataxia
Alessia Nasca1∗ Chiara Scotton2∗ Irina Zaharieva3 Marcella Neri2
Rita Selvatici2 Olafur ThorMagnusson4 Aniko Gal5,6 DavidWeaver5
Rachele Rossi2 Annarita Armaroli2 Marika Pane7 Rahul Phadke3
Anna Sarkozy3 FrancescoMuntoni3 Imelda Hughes8 Antonella Cecconi9
György Hajnóczky5 Alice Donati10 EugenioMercuri7 Massimo Zeviani11
Alessandra Ferlini2,3∗ Daniele Ghezzi1∗
1MolecularNeurogeneticsUnit, Foundation IRCCSNeurological Institute Besta,Milan, Italy
2Medical GeneticsUnit, Department ofMedical Sciences, University of Ferrara, Ferrara, Italy
3DubowitzNeuromuscular Centre, UCLGreatOrmond StreetHospital, London, UK
4deCODEGenetics, Reykjavik, Iceland
5MitoCareCenter forMitochondrial Imaging Research andDiagnostics, Department of Pathology, Anatomy andCell Biology, Thomas JeffersonUniversity,
Philadelphia, Pennsylvania
6Institute ofGenomicMedicine andRareDisorders, SemmelweisUniversity, Budapest, Hungary
7NeuropsichiatryUnit, Catholic University, PoliclinicoGemelli, Rome, Italy
8RoyalManchester Children’sHospital,Manchester, UK
9PediatricsMedical Genetics, Hospital S.Maria Annunziata Bagno aRipoli, Florence, Italy
10Unit ofMetabolic andMuscularDiseases,MeyerChildrenHospital, Florence, Italy
11Mitochondrial BiologyUnit -MRC, Cambridge, UK
Correspondence
DanieleGhezzi,Unit ofMolecularNeurogenet-
ics, Foundation IRCCS InstituteofNeurology
“Besta”, viaTemolo, 4, 20126Milan, Italy.
Email: daniele.ghezzi@istituto-besta.it
AlessandraFerlini,Unit ofMedicalGenetics,
University of Ferrara,ViaFossatodiMortara, 74,
44121Ferrara, Italy.
Email: fla@unife.it; a.ferlini@ucl.ac.uk
MassimoZeviani,MRCMitochondrial Biology
Unit,WellcomeTrust/MRCBuilding,HillsRoad,
Cambridge,CB20XY,UK.
Email:mdz21@mrc-mbu.cam.ac.uk
∗AlessiaNasca,Chiara Scotton,Alessandra
Ferlini, andDanieleGhezzi contributedequally
to this study.
Communicatedby JohannesZschocke
Abstract
We report here the first families carrying recessive variants in the MSTO1 gene: compound
heterozygous mutations were identified in two sisters and in an unrelated singleton case, who
presented a multisystem complex phenotype mainly characterized by myopathy and cerebellar
ataxia. Human MSTO1 is a poorly studied protein, suggested to have mitochondrial localization
and to regulate morphology and distribution of mitochondria. As for other mutations affecting
genes involved in mitochondrial dynamics, no biochemical defects typical of mitochondrial
disorders were reported. Studies in patients’ fibroblasts revealed that MSTO1 protein levels
were strongly reduced, the mitochondrial network was fragmented, and the fusion events among
mitochondria were decreased, confirming the deleterious effect of the identified variants and
the role of MSTO1 in modulating mitochondrial dynamics. We also found that MSTO1 is mainly
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a cytosolic protein. These findings indicate recessive mutations in MSTO1 as a new cause for
inherited neuromuscular disorders withmultisystem features.
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Mitochondria are highly dynamic organelles, which undergo con-
stant fusion and fission events, and cristae remodeling. Mitochon-
drial dynamics influences several homeostatic and execution path-
ways involving the organelle and other compartments of the cell,
and is in turn controlled by intraorganellar and extraorganellar
metabolic requirements and signals, including the availability of nutri-
ents, cell cycle, and calcium homeostasis. Mitochondrial fusion allows
the exchange of damaged mitochondrial DNA (mtDNA) and proteins
between impaired and “healthy” mitochondria, whereasmitochondrial
fission facilitates their redistribution inside the cell (Okamoto & Shaw,
2005) and the isolation of faulty mitochondria, which can then be
eliminated bymitophagy. Fragmentation of themitochondrial network
is also observed just before apoptosis (Munoz-Pinedo et al., 2006).
Mitochondrial dynamics is mainly controlled by a group of proteins
belonging to the dynamin superfamily of GTPases. The typical struc-
ture of dynamin-related proteins consists of a large amino-terminal
GTPase domain, amiddle domain, and aGTPase effector domain (Prae-
fcke &McMahon, 2004). DNM1L (dynamin-1-like, MIM# 603850) is a
cytosolic GTPase that localizes to the outer mitochondrial membrane
and carries out mitochondrial fission. Other members of the dynamin
family are involved in mitochondrial fusion: mitofusins (MFN1, MIM#
608506, andMFN2, MIM# 608507) localize to and operate the fusion
of the mitochondrial outer membrane (Chen et al., 2003), whereas
OPA1 (MIM# 605290) is a multitasking protein of the inner mem-
brane, where it promotes fusion, cristae remodeling, and sealing of
cristae junctions (Alexander et al., 2000; Delettre et al., 2000). Very
recently, dynamin-2 (DNM2, MIM# 602378) has been reported to be
a fundamental component of themitochondrial fissionmachinery (Lee,
Westrate,Wu, Page, & Voeltz, 2016).
The human gene MSTO1 encodes the ortholog of misato of
D. melanogaster. Misato proteins are conserved from yeast to human.
Their function is still controversial, but they share regions homologous
to a GTPase subfamily (Miklos, Yamamoto, Burns, & Maleszka, 1997)
that includes tubulin andbacterial FtsZ, regulating segregationof chro-
mosomes, and fission of both chloroplasts and mitochondria. Human
MSTO1 is ubiquitously expressed (Kimura & Okano, 2007) and was
reported to localize mainly to mitochondria. RNAi-mediated MSTO1
knockdown causesmitochondrial fragmentation, whereas overexpres-
sion of recombinant MSTO1 induces aggregation of mitochondria at
the perinuclear region (Kimura &Okano, 2007).
Several mutations in genes-encoding factors mediating mitochon-
drial fission or fusion have been associatedwith diverse human genetic
diseases, with predominant neurological involvement. For instance,
mutations in MFN2, OPA1, DNM1L, and MFF (encoding mitochondrial
fission factor) cause Charcot–Marie–Tooth disease type 2A (MIM#
609260), dominant optic atrophy (MIM#165500), and severe infantile
encephalomyopathies (MIM#614388;617086), respectively.Here,we
report a family of four with two sisters, presenting with severe con-
genital myopathy and cerebellar ataxia associatedwith skeletal abnor-
malities and mild mental retardation as corollary symptoms of a mul-
tisystem disease. Whole-exome sequencing (WES) analysis identified
a compound heterozygous genotype of two missense mutations in
MSTO1.Functional characterization ofmutant cells demonstrated pro-
found MSTO1 reduction in patients’ fibroblasts. Different compound
heterozygous variants in MSTO1 were found by WES also in a single-
ton case presenting a dystrophic myopathy and cerebellar ataxia. Our
results demonstrate thatMSTO1 is a novel disease gene causing amito-
chondrial morphology defect and leading to a muscular recessive dis-
ease (ranging from congenital myopathy to muscular dystrophy) with
multisystem involvement.
Detailedmethods for biochemical assays,molecular genetics, struc-
tural and protein analyses, fluorescence microscopy, and functional
studies in cells are reported in Supp. Information.
Informed consent for genetic and biochemical studieswas obtained
from the parents of patients, in agreement with the Declaration of
Helsinki and approved by the Ethical Committees of the Meyer Chil-
dren Hospital, Florence, Italy, and of the Health Research Authority,
NRES Committee East of England –Hatfield.
Patient A1 is the first daughter of unrelated parents (II-1, family A;
Fig. 1A). Family history is negative for neurological and skeletal dis-
orders. Pregnancy was uneventful, but was interrupted prematurely
by caesarean delivery due to acute fetal distress. The child showed
neonatal distress (Apgar 5–7), but her psychomotor development was
reported as normal in the first months after birth. However, from 8
to 9 months of age, severe growth and motor delay became progres-
sively obvious. A brain MRI at 18 months revealed severe hypotrophy
of cerebellar vermis, with an enlarged cisterna magna, and hyperin-
tense signals in the supratentorial periventricular and posterior white
matter. At 5 years of age, the patient showed severe growth impair-
ment (<3rd percentile for both weight and height), had fine tremors
and no autonomous walk, but normal muscle tone and normal cog-
nitive development. At 7 years of age, a brain MRI disclosed global
cerebellar hypotrophy, with reduction of the N-acetyl aspartate peak
at proton magnetic resonance spectroscopy ([1H+]-MRS), and abnor-
mal signal in the supratentorial peritrigonal white matter. These find-
ings were confirmed at 16 years of age (Fig. 1B and C). Ophthalmologi-
cal examination revealed the presence of pigmentary retinopathy with
papillarypallor, associatedwith concentric restrictionof thevisual field
but no abnormality of visual acuity. Electromyography (EMG) exami-
nation revealed a myopathic pattern, and a muscle biopsy confirmed
the presence of myopathic features with high variability in muscle
fiber diameter hypotrophic, polygonal fibers and hypertrophic, round
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F IGURE 1 Clinical, biochemical, and genetic features of theMSTO1mutant patients A1 and A2. A: Pedigree of the family A with the identified
MSTO1 variants. Black symbols indicate the affected siblings.B andC: BrainMRI (B: sagittal;C: coronal images) of the patient A1, taken at 16 years
of age, showing cerebellar hypotrophy. D: Skeletal abnormalities of patient A1 (17 years of age), with marked scoliosis and severe asymmetry of
the chest and pectus excavatum. Consent to publish anonymized photos was obtained from patients’ parents. E: Activities of the mitochondrial
respiratory chain (MRC) complexes (cI, cII, cIII, cIV) inmuscle homogenates frompatients A1 andA2, reported as percentages of the controlsmean.
The specific activities were normalized for citrate synthase (CS) activity. The dotted line represents the minimum value of the control range. F:
QuantificationofmtDNAamount inmuscle frompatientA1and3controls (Ct1-3). Thebars represent the amount ofmtDNAnormalized tonuclear
DNA (nDNA), comparedwith themeanvalueof controls (=1).Data are represented asmean±SDof four independent experiments.G: Dysmorphic
traits of patient A2: triangular face, with sunken eyes, severe asymmetry of the chest and pectus excavatum. H: Schematic representation of the
MSTO1 protein withmain functional domains and localization of the identifiedMSTO1mutations in family A (red variants) and B (blue variants)
fibers, and scattered fibers with intracytoplasmic microvacuolizations.
No oxidative histochemical defect in mitochondrial enzymes (COX,
SDH) was observed. Plasma CK was elevated (≈1,200 U/L, n.v. <250),
and reduced citrullin levels were consistently found in plasma. The
patient showed severe asymmetry of the chest, with enlargement of
the right hemithorax, pectus excavatum, andmarked scoliosis (Fig. 1D).
She was able to stand but could not walk autonomously. Her face is
peculiar with thick hair and a high-arched palate. Biochemical assays
of muscle homogenate showed no abnormality of the mitochondrial
respiratory chain, but citrate synthase activity, an index of mitochon-
drial mass, was markedly reduced (36 nmol/min/mg, n.v. 80–210; Fig.
1E). mtDNA amount was reduced to 27% of the mean control value
(Fig. 1F). The following genes were previously excluded by Sanger
sequencing: SPG7, FKTN, POMT1, POMT2, LARGE, POMGNT1, and SIL1.
The presence of pathogenic mtDNAmutations was also ruled out. The
patient is now 17 years old, in stable condition, with severely impaired
motor function, severe skeletal abnormalities, but no cognitive
deficiency.
Patient A2, the younger sister of patient A1 (II-2, family A; Fig.
1A), was born by cesarean section after an uneventful pregnancy. Her
clinical course has been similar to that of patient A1, including the
presence of cerebellar hypotrophy with no autonomous walk, adiado-
chokinesia, dysmetry and fine tremors; she shows muscle weakness,
pes cavus, and reduced deep tendon reflexes. An EMG revealed a
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predominantly myopathic pattern, associated with high plasma levels
of CK (1,872U/L) and low plasma levels of citrullin (14 𝜇M, n.v. 17–53).
Her cognitive development has been normal but, like her affected
sister, she showed severe growth impairment since 8–9 months of
age; facial (Fig. 1G) and hair abnormalities and asymmetry of the
thorax were similar to those of her sister, but she showed no organic
aciduria and normal acylcarnitines in plasma and urine. Ophthalmo-
logical examination revealed bilateral papillary pallor, but pigmentary
retinopathy, reduced visual acuity, and nystagmus were absent. A
muscle biopsy showed a myopathy with dystrophic features, with
vacuolization of scattered muscle fibers, increased perimysial- and
endomysial connective tissue, and partial reduction of COX histoen-
zymatic reaction. Biochemical assays revealed partial complex II defi-
ciency (52% residual activity) and severely reduced citrate synthase
activity (44 nmol/min/mg; Fig. 1E). No residualmusclewas available for
further analyses. The patient is now 13 years old, in a stable condition.
Patient B is a 7-year-old child of British Caucasian descent, born
to nonconsanguineous parents (family B); he has a healthy older sis-
ter. He presented at around 1 year of age with reluctance to stand
and walk unsupported. Subsequently, he showed difficulty walking
long distances, getting up from the floor, and frequent falls. Speech
acquisition was delayed. Gradual improvement in motor activities was
then noted and, at the age of 3.5 years, he was able to walk half
a mile, although with frequent falls, and he acquired the ability to
walk upstairs. Gowers’ time from lying was 6.4 sec. At the age of
6 years, he showed further improvement, showing less falls and a
Gower’s time of 3.6 sec. Weakness was proximal more than distal,
affecting lower limbs (MRCpowergrade3–4/5)more thanupper (MRC
power grade 4/5), with the exception of the peroneal muscles that
were MRC power grade 3+/5. He presents mild end of range tight-
ness of Achilles tendons but no other joint contractures. Deep ten-
don reflexes were present and symmetric; Babinski was negative. A
degree of poor coordination, especially of the left hand, was notice-
able from the age of 3 years. At the age of 6 years, he showed a
fine intentional tremor bilaterally at finger-nose test, dysdiachokine-
sia and difficulties with rapid hands repeated movements but no nys-
tagmus. He shows no cognitive involvement but presents problems
related to speech articulation.Hehas no cardiac or respiratory involve-
ment, and forced vital capacity was 91% of predicted values. Oph-
thalmological examinationwas normal. An EMG/NCS showed changes
compatible with a myopathic process. Brain MRI at the age of 3.5
years showed hypoplasia of cerebellar vermis and hemispheres (Supp.
Fig. S1). These findings remained static at a follow up of 2 years.
Serum CKwas 4,520 IU/L and serum lactate and transferrin were nor-
mal. Right thigh muscle biopsy at 2 years showed dystrophic changes
with nonrimmed vacuoles. Oxidative histochemistry (COX, SDH) did
not show COX- or SDH-deficient activities. Ultrastructural examina-
tion showed striking vacuolar degeneration of mitochondria (Supp.
Fig. S2).
Mutations in known genes causative of muscular dystrophies and
vacuolar myopathies were excluded first by a gene panel analysis, and
direct Sanger sequencing of a number of limb girdle muscular dystro-
phy genes was also performed. Further search of mutations in less
common neuromuscular genes was excluded by WES data analysis.
Variants were first prioritized according to a homozygous-recessive
model, but no variants were found. Therefore, variants were pri-
oritized according to the presence of compound heterozygosity
based on recessive inheritance and on the nonconsanguinity of
the parents. In the two affected siblings of family A (A1 and A2),
two novel missense mutations were identified in MSTO1, a gene
regulating mitochondrial distribution and morphology, not previ-
ously associated with human diseases (Supp. Fig. S3) (GenBank
accession no. NM_018116.3): c.1033C>T; p.R345C and c.1128C>A;
p.F376L (Fig. 1H). The R345 and F376 are highly conserved residues
(Supp. Fig. S4A), and the corresponding variants have never been
reported in publicly available databases [http://www.ncbi.nlm.nih.gov/
SNP; http://browser.1000genomes.org/index.html; http://exac.broadi
nstitute.org; ], excepting 1 out of>120,000 alleles with the c.1033C>T
(rs150075701) in ExAC database. Sanger sequencing in the probands
and their parents confirmed the presence of the (maternal) c.1033C>T
and the (paternal) c.1128C>A variants in both patients (A1 and A2), as
expected for an autosomal-recessive nonconsanguineous inheritance
(Supp. Fig. S4A; Fig. 1A). Following this finding, we searched for addi-
tional patients with pathogenic variants inMSTO1 in theWES datasets
fromcongenitalmyopathy and congenitalmuscular dystrophy patients
analysedwithin the NeurOmics project. In patient B, we identified two
heterozygous MSTO1 mutations: c.971C>T; p.T324I and a nucleotide
change c.966+1G>A affecting the consensus splice site of exon 9 (Fig.
1H). Sanger sequencing confirmed the segregation of the mutations
with the disease within the family (Supp. Fig. S5). Both varaints are
present in the ExAC database at very low frequency compatible with
rare recessive disorder (allele frequency< 0.00004).
In order to evaluate the effect of the identified MSTO1 variants
on transcript and protein, we studied available specimens from the
patients. For A1 and A2, we used skin fibroblasts: quantitative PCR
analysis of the retrotranscribed MSTO1 cDNA showed partial reduc-
tion of transcript amount (Supp. Fig. S6A) in both cell lines, but
no aberrant species were observed. Notably, the total amount of
MSTO1 protein detected by western blot (WB) analysis was drasti-
cally reduced in patients’ fibroblasts compared with controls (∼15%
residual amount; Fig. 2A); a strong reduction in MSTO1 was also
observed in immortalized fibroblasts from A1 (Supp. Fig. S6B). These
findings confirmed the deleterious effect of these two MSTO1 vari-
ants, probably affecting the stability of the protein. For patient B, we
analyzed skeletal muscle: transcript analysis of cDNA obtained from
retrotranscribed RNA showed the presence of an aberrant transcript
that was found to lack exon 9. This finding confirmed the deleteri-
ous effect of the c.966+1G>A on splicing (Supp. Fig. S7). Then, we
tested the antibody on total lysate, but no immunoreactive signal was
observed at the expected molecular weight even in control samples
(Supp. Fig. S7), suggesting that the antibody does not work on muscle
homogenate.
Given the predicted role of MSTO1 in regulating mitochondrial
morphology (Kimura & Okano, 2007), we evaluated the functional
consequences of the MSTO1 variants by assessing the mitochondrial
network in patients’ fibroblasts. Fibroblasts grown in either stan-
dard glucose or galactose medium were stained with a mitochondrial
dye (Mitotracker) and examined by fluorescence microscopy. Patients’
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F IGURE 2 Characterization of fibroblast cell lines. A: MSTO1 protein amount in patients’ (A1 and A2) and control (CT1 and CT2) fibroblasts,
obtained using an anti-MSTO1 antibody. An anti-GAPDH antibody was used as a loading control. B: Mitochondrial morphology, assessed in pri-
mary and pRNS1-immortalized fibroblasts from patient A2 and controls (Pt and CT, iPt and iCT, respectively), was scored as follows: “Fragmented”,
mainly small and round; “Partly fragmented”, intermediate, mixture of round and shorter tubulated; “Normal”, tubulated, long and higher intercon-
nectivity; “Elongated”, very long, tubulated. The percentage of cells with indicatedmitochondrial morphologies was determined as a percentage of
the total number ofMitoTracker Green loaded cells counted (number of cells: CT= 145, Pt= 160; iCT= 191; iPt= 220).C: Representative images
of mitochondrial morphology (obtained with MitoTracker red), showing the filamentous mitochondrial network of fibroblasts from a control (CT),
and the fragmented network in patients’ (A1 and A2) cells, grown in glucose medium. Scale bar: 25 𝜇m.D: Mitochondrial continuity in primary and
pRNS1-immortalizedfibroblasts. The time course of theF ratio ofmtPA-GFP (G-Gbase/Gmax-Gbase) for the regionof photoactivation (RPA) (left); the
decay of the fluorescence ratio in the RPA at 500 sec (right). (Number of imaged cells: CT= 20; Pt= 21; iCT= 23; iPt= 25; from three experiments
per each cells). Stars indicate significant differences (P<0.05)
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cells showed a clear fragmentation of the mitochondrial network
compared with controls. Altered mitochondria were also more abun-
dant in immortalized fibroblasts from patient A1 than from controls
(Fig. 2B and C). To evaluate whether the fragmented mitochondrial
morphology in patient and control fibroblasts can result from sup-
pressed mitochondrial fusion activity, cells were cotransfected with
a mitochondrial marker (mtDsRed) and a mitochondrial photoactivat-
able GFP (mtPA-GFP). The diffusion of the photo-activatedmtPA-GFP
was reduced in patients’ cells, indicating a decrease in the combined
activity of mitochondrial network formation, mitochondrial fusion,
and mitochondrial movements (Fig. 2D). The fusion events, validated
by reciprocal spreading of mtPA-GFP and mtDsRed, were fewer and
lasted slightly longer in patients’ cells than in controls (Supp. Fig. S8).
Thus, suppression of mitochondrial fusion is likely a cause of the frag-
mented mitochondrial morphology in MSTO1 patients. Since some of
the proteins involved in mitochondrial dynamics (e.g., DNM1L, MFF)
are also involved in peroxisomal morphology, we did check this aspect
by immunofluorescence using an antiperoxisomal antibody (PMP70):
in patients’ cells, we observed a normal morphology and distribution
of peroxisomes that had only a slightly, not significantly, reducedmean
area comparedwith control cells (Supp. Fig. S9A and B).
In accordance with the reduced mtDNA content observed in mus-
cle fromA1, the amount ofmtDNA in total DNAextracted fromfibrob-
lasts, assessed by quantitative PCR, was also lower in the patients than
in controls (39% and 68% of the mean control value for A1 and A2,
respectively); nevertheless, by Picogreen staining, we did not observe
any evident alteration (e.g., perinuclear clustering) in mitochondrial
nucleoid distribution (Supp. Fig. S9C). Respiratory capacity, assessed
by SeaHorsemicro-oxygraphy, aswell as citrate synthase activity,were
normal in patients’ fibroblasts (not shown).
MSTO1 was previously suggested to be a mitochondrial protein,
localized in the outer membrane (Kimura & Okano, 2007), but sev-
eral bioinformatics tools for prediction of the subcellular localization
indicated MSTO1 as a cytosolic protein, not targeted to mitochon-
dria (Supp. Table S1). Moreover, in our WB experiments, the intensity
of the anti-MSTO1 immunoreactive band was lower in mitochondrial-
enriched preparations compared with total lysates; hence, we decided
to investigate the localization of MSTO1 by WB immunodetection on
HeLa cell subfractions. This analysis revealed thatMSTO1was present
in the 13,000g supernatant, corresponding to the postmitochondrial
fraction, but not in the mitochondria-containing 13,000g pellet. Ultra-
centrifugation of the postmitochondrial supernatant at 100,000g indi-
cated thatMSTO1 is a soluble protein present in the 100,000g (cytoso-
lic) supernatant but absent in the corresponding (microsomal) pellet
(Supp. Fig. S10). Notably, the distribution of MSTO1 upon differential
centrifugation is similar to that of DNM1L (also known asDRP1). Since
the antibody againstMSTO1was not suitable for immunofluorescence
studies, we expressed a HA-tagged MSTO1 protein (MSTO1-HA) in
HeLa cells. The HA signal was distributed throughout the cytoplasm
with only partial colocalization with a mitochondrial marker, whereas
no signal was detected in the nucleus (Supp. Fig. S10), thus confirm-
ing the results of the immunoblot experiments. The same pattern
was observed also in COS7 cells transfected with MSTO1-HA (Supp.
Fig. S11).
Next, we tested whether the expression of wild-type MSTO1 could
recover the fragmented mitochondrial network observed in mutant
fibroblasts. To avoid artifacts caused by fixation, we analyzed the
effect ofMSTO1 expression on mitochondria in live cells. MSTO1 was
cotransfected with a GFP targeted to mitochondria (mtGFP) in order
to easily identify cells expressing the exogenous proteins (Supp. Fig.
S12). After transient overexpression of wild-type MSTO1 in mutant
and control fibroblasts, we observed that the mitochondrial network
was unaffected at 24 hr, but at 48 hr, most of the cells with green sig-
nal collapsed, detached from the plate or floating in the medium; only
a few cells were still adherent but showed fragmentation and perinu-
clear aggregation of mitochondria, both in patients and control cells
(Supp. Fig. S13). At 72 hr, no cells with green signal were found. Con-
trariwise, the single transfection of mtGFP had no major effect on the
viability of fibroblasts and on the mitochondrial network even after
>96 hr (not shown). These findings suggest that the overexpression
of MSTO1 is deleterious, as already reported by Kimura and Okano
(2007),whoobserved reducedvitality andperinuclear clusters ofmito-
chondria after overexpression ofMSTO1-GFP in COS7 cells.
TheWES analysis in our familieswithmyopathy and ataxia revealed
that mutations of MSTO1 can be a new genetic cause for rare human
disease, impairing themitochondrial dynamicmaintenance circuit. The
fragmented mitochondrial network observed in mutant cells and vac-
uolar degeneration of mitochondria are in agreement with the pro-
posed role of MSTO1 in mitodynamics. In fact, RNAi-driven MSTO1
depletion leads to mitochondrial fragmentation, whereas overexpres-
sion of human EGFP-tagged MSTO1 causes alterations in mitochon-
drial morphology and aggregation of mitochondria in the perinuclear
region (Kimura & Okano, 2007). This was supported also by evidence
from studies on S. cerevisiae, where expression of DML1, the bona
fide yeast ortholog of MSTO1, leads to mitochondrial dispersion and
abnormalities in cell morphology (Gurvitz, Hartig, Ruis, Hamilton, & de
Couet, 2002). Taken together, these findings suggest that MSTO1 is
either a profusion protein, which promotes the formation of the tubu-
lar network, or anantifission factor,which inhibits the activity of profis-
sion proteins such as DNM1L. Our data indicate thatMSTO1 is largely
cytosolic: this result is in contrast with those of Kimura and Okano
(2007), who reported a loose association with the mitochondrial outer
membrane. However, it is possible that MSTO1 may have the same
behavior of DNM1L, which is a cytosolic protein that translocates to
the outer membrane to carry out mitochondrial fission (Bleazard et al.,
1999; Smirnova, Griparic, Shurland, & van der Bliek, 2001).
Given its homology with eukaryotic tubulin and prokaryotic FtsZ
(Gurvitz et al., 2002; Miklos et al., 1997), MSTO1 was initially pro-
posed to regulate chromosome segregation and cell division; accord-
ingly, Misato mutations in D. melanogaster were associated with
irregular chromosome segregation during mitosis (Miklos et al., 1997).
Some clinical features in our patientsA1 andA2, such as skeletal devel-
opmental abnormalities (e.g., pectus excavatum) and mild dysmorphic
features do suggest a possible involvement of nuclear chromosomal
DNA, whereas other abnormalities, such as cerebellar hypotrophy,
leukodystrophy, and myopathic/dystrophic changes, possibly leading
to additional skeletal deformities such as scoliosis, are often associated
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with mitochondrial impairment. However, considering that the lar-
vae of MSTO1 mutant flies showed severe morphological abnormali-
ties and early death, the phenotype presented by our patients seems
milder, suggesting a hypomorphic effect of the identifiedMSTO1 vari-
ants. Another possibility is that the function of the proteinmay diverge
between arthropoda and humans.
Most of the patients with mutations in genes related to mitody-
namics presented a neurological phenotype; our MSTO1-mutant sub-
jects have indeed amyopathy associatedwith cerebellar ataxia, under-
lined by hypotrophy of the cerebellar vermis; the sisters A1 and A2
also present amultisystem conditionwith developmental delay, partic-
ularly motor impairment with ataxia and dysmorphisms.
Our biochemical analyses were not indicative of a mitochondrial
disorder: patients showed normal lactate levels, and hardly any defect
of MRC complex activities or cell respiration, as frequently seen in
other defects of mitodynamics, such as OPA1 (Mayorov et al., 2008)
and DNM1L mutations (Nasca et al., 2016). However, we detected
markedly low activity of citrate synthase and reducedmtDNA amount,
suggesting a reduction in mitochondrial mass. Although these alter-
ations can be due to dystrophic changes in the muscle biopsies, the
lowmtDNA content observed in patients’ fibroblasts supports the pre-
vious hypothesis. Interestingly, reduced plasma citrullin was found in
both siblingsA1 andA2: hypocitrullinemiawas reported in some inher-
ited disorders affectingmitochondrial function andwas suggested as a
biomarker of oxidative stress (Atkuri et al., 2009).
Our study confirms the proposed role for MSTO1 in regulat-
ing mitochondrial morphology, favoring fusion versus fission events,
despite itsmainly cytoplasmic localization.We showed that compound
heterozygous recessive mutations in MSTO1 lead to impairment of
mitochondrial dynamics, and are associated, in our affected patients,
with a disease characterized by neurological, muscular, and sometimes
skeletal involvement. Notably, a family with an autosomal-dominant
mutation in MSTO1 was recently identified (Gal et al., 2016), with the
affected subjects presenting symptoms partly overlapping those of our
patients, for example,myopathy, ataxia, skeletal alterations, in addition
to psychotic features, for example, schizophrenia or autism, which are
not present in our cases. Certainly, investigation on further patients is
required to better define themode of inheritance and the clinical spec-
trum ofMSTO1-related disease.
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